Literature DB >> 26226951

The role of type I hypersensitivity reaction and IgE-mediated mast cell activation in acute interstitial nephritis.

Ladan Zand, Myles Monaghan, Benjamin R Griffin, Steven J Wagner, Iasmina M Criaci, Afrin Kamal, Yassaman Raissian, Joseph P Grande, Kaiser G Lim, Vesna D Garovic.   

Abstract

BACKGROUND: Acute interstitial nephritis (AIN) presents with acute kidney injury, with evidence of interstitial inflammation and tubulitis on histology, and the presence of fever, rash, and eosinophiluria. Although the pathogenesis of this disease is not well understood, cell-mediated immunity is thought to play a major role. We hypothesized that IgE mediated mast cell activation is also involved in the pathogenesis of renal injury in AIN.
METHODS: 28 patients, with biopsy proven AIN over a 5-year period, were included in this study. Clinical data, including renal outcomes and the etiologies of AIN, were evaluated in all patients. Available tissues (renal biopsy) from 26 of the patients were stained for β-tryptase (marker for mast cell degranulation), IgE, IL-16, and CD3. A negative control for immunostaining was included.
RESULTS: Samples from all 26 individuals stained positive for β-tryptase (mean of 11.16 cells/high power field), IgE (mean average of 0.68 cells/HPF), IL-16 (28% of the interstitium), and CD3 (33% of the interstitium). Acute interstitial nephritis was due to medication in 73%, systemic disease in 15%, and unknown (idiopathic) in 12% of the cases. 86% of patients were treated with corticosteroids. 18% required acute inpatient dialysis, with 7% remaining on dialysis longterm.
CONCLUSIONS: Our study suggests that IgE and mast cell activation may play a role in the pathogenesis of AIN.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26226951     DOI: 10.5414/CN108254

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Treatment of Drug-Induced Acute Tubulointerstitial Nephritis: The Search for Better Evidence.

Authors:  Dennis G Moledina; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-05       Impact factor: 8.237

Review 2.  Differentiating Acute Interstitial Nephritis from Acute Tubular Injury: A Challenge for Clinicians.

Authors:  Dennis G Moledina; Chirag R Parikh
Journal:  Nephron       Date:  2019-06-14       Impact factor: 2.847

3.  Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis.

Authors:  Dennis G Moledina; F Perry Wilson; Jordan S Pober; Mark A Perazella; Nikhil Singh; Randy L Luciano; Wassim Obeid; Haiqun Lin; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Lloyd G Cantley; Chirag R Parikh
Journal:  JCI Insight       Date:  2019-05-16

4.  The Challenges of Acute Interstitial Nephritis: Time to Standardize.

Authors:  Dennis G Moledina; Mark A Perazella
Journal:  Kidney360       Date:  2021-04-01

Review 5.  Drug-Induced Acute Kidney Injury.

Authors:  Mark A Perazella; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-10       Impact factor: 10.614

6.  Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.

Authors:  Lea Bottlaender; Anne-Laure Breton; Louis de Laforcade; Frederique Dijoud; Luc Thomas; Stephane Dalle
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.